MIRA Pharmaceuticals, Inc. Common Stock (NASDAQ:MIRA) — Market Cap & Net Worth
Market Cap & Net Worth: MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
MIRA Pharmaceuticals, Inc. Common Stock (NASDAQ:MIRA) has a market capitalization of $40.96 Million ($40.96 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22713 globally and #4921 in its home market, demonstrating a 0.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MIRA Pharmaceuticals, Inc. Common Stock's stock price $0.98 by its total outstanding shares 41876087 (41.88 Million). Review MIRA Pharmaceuticals, Inc. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
MIRA Pharmaceuticals, Inc. Common Stock Market Cap History: 2023 to 2026
MIRA Pharmaceuticals, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $43.97 Million to $40.96 Million (-50.59% CAGR).
Index Memberships
MIRA Pharmaceuticals, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #651 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2164 of 3165 |
Weight: MIRA Pharmaceuticals, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MIRA Pharmaceuticals, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MIRA Pharmaceuticals, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MIRA by Market Capitalization
Companies near MIRA Pharmaceuticals, Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to MIRA Pharmaceuticals, Inc. Common Stock by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $564.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1112.00 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $564.26 Billion | $234.20 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $221.23 |
MIRA Pharmaceuticals, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, MIRA Pharmaceuticals, Inc. Common Stock's market cap moved from $43.97 Million to $ 40.96 Million, with a yearly change of -50.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $40.96 Million | -35.22% |
| 2025 | $63.23 Million | +32.46% |
| 2024 | $47.74 Million | +8.57% |
| 2023 | $43.97 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of MIRA Pharmaceuticals, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.96 Million USD |
| MoneyControl | $40.96 Million USD |
| MarketWatch | $40.96 Million USD |
| marketcap.company | $40.96 Million USD |
| Reuters | $40.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more